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A B S T R A C T
The antibiotic crisis has reinstated polymyxins, once abandoned because of their toxicity. Now, preclinical
studies have revealed better tolerated and more effective derivatives of polymyxins such as NAB739.
Simultaneously, polymyxin-resistant (PMR) strains such as the mcr-1 strains have received lots of justified
publicity, even though they are still very rare. Here we show that NAB739 sensitizes the PMR strains to rifampin,
a classic “anti-Gram-positive” antibiotic excluded by the intact outer membrane (OM) permeability barrier, as
well as to retapamulin, the surrogate of lefamulin, an antibiotic under development against Gram-positive
bacteria. Polymyxin B was used as a comparator. The combination of NAB739 and rifampin was synergistic
against ten out of eleven PMR strains of Escherichia coli (Fractional Synergy Indices, FICs, 0.14-0.19) and that of
NAB739 and retapamulin against all the tested eleven strains (FICs 0.19-0.25). Against PMR Klebsiella pneu-
moniae (n=7), the FICs were 0.13-0.27 for NAB739+ rifampin and 0.14-0.28 for NAB739+retapamulin.
Against Acinetobacter baumannii (n=2), the combination of NAB739 and rifampin had the FIC of 0.09-0.19.
Furthermore, NAB739 and meropenem were synergistic (FICs 0.25-0.50) against four out of five PMR strains that
were simultaneously resistant to meropenem.
1. Introduction
Carbapenems have become last-line drugs against extensively drug-
resistant (XDR) strains of Enterobacteriaceae and Acinetobacter bau-
mannii. Now, the global dissemination of strains carrying carbapene-
mases has resulted in limited therapeutic options [1–6]. Low serum and
urine levels shadow the use tigecycline [5], whereas ceftazidime-avi-
bactam (CZA) is confronted by emerging resistance [6] and is not ef-
fective against enzymes that belong to the metallo-β-lactamase group.
Previously in 2010, the World Health Organization (WHO) stated that
antibiotic resistance is one of the three greatest threats to human
health. Today, and quite alarmingly, only a few novel antibiotics
against the XDR strains are under development, as also reported re-
cently by WHO [7]. It follows that, as the search for novel antibacterial
agents is more pertinent than ever, it is important to maximize the
potential of the current antibiotics.
Polymyxins (polymyxin B [PMB] and colistin, Table 1) are cyclic
lipodecapeptide antibiotics, highly basic due to five free amino groups
and effective against Gram-negative bacteria such as the majority of
Enterobacteriaceae, as well as A. baumannii and Pseudomonas aerugi-
nosa. The discovery of polymyxins was published independently by
three laboratories in 1947. Their clinical use was abandoned in the
1960s due to nephrotoxicity and the introduction of better-tolerated
drugs belonging to other antibiotic classes. Now, polymyxins have seen
a resurgence as the last-line drugs against XDR strains. However, even
this new role is in jeopardy. The recent appearance of mobile colistin
resistance (mcr) genes has elicited much concern and publicity, but
strains resistant to polymyxins by other mechanisms such as those with
altered mgrB are also worrisome and should not be overlooked [8–11].
In 2013, Tascini et al. showed that there is notable synergism with
colistin and rifampin against polymyxin-resistant (PMR), carbapene-
mase-producing Klebsiella pneumoniae [12]. Very recently (2018), two
publications have highlighted the potential of polymyxin-based com-
binations against PMR strains in a detailed way. MacNair et al. showed
that colistin is notably synergistic in vitro with rifampin, the macrolide
antibiotic clarithromycin, minocycline, and novobiocin against mcr
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strains [13]. Brennan-Krohn et al. described the synergism of colistin
with rifampin, the macrolide antibiotic azithromycin, minocycline, fu-
sidic acid, linezolid, and several other drugs against mcr and other PMR
strains [14]. A plausible explanation for the synergism is that even
though the PMR strains can grow at higher concentrations of poly-
myxins than the polymyxin-susceptible wild-type strains, subinhibitory
concentrations of polymyxins are still able to damage the outermost
permeability barrier, the outer membrane (OM) of the PMR bacteria.
Consequently, the damaged OM allows the entry of drugs normally
excluded or partially excluded by the intact enterobacterial OM [13,14]
NAB739 is a novel polymyxin derivative [15,16]. It carries only
three positive groups, all in strategic positions, instead of five in PMB
and colistin (Table 1). Since complicated urinary tract infections (cUTI)
caused by XDR strains and proceeding to septic shock are a major
concern, compounds like NAB739 may be clinically useful. In a 7-day
cynomolgus monkey study, NAB739 yielded at equal doses urinary
concentrations ten-fold compared to those of PMB [16]. In a murine
E.coli pyelonephritis model, NAB739 was effective at a dose one tenth
of that of PMB, even though the MIC of NAB739 against the challenge
strain was higher than that of PMB (2mg/L vs. 0.5 mg/L) [17]. Fur-
thermore, NAB739 is less nephrotoxic to cynomolgus monkeys than
PMB [16].
Herein we show that NAB739 acts against PMR strains synergisti-
cally with rifampin, the classic compound used in polymyxin synergism
studies [15,16,18–20]. Additionally, we report synergism with re-
tapamulin, a pleuromutilin antibiotic and surrogate of lefamulin [21],
an antibiotic effective against Gram-positive bacteria only and currently
in late clinical development by Nabriva Therapeutics for both oral and
intravenous administration [22]. We chose rifampin and retapamulin to
represent model antibiotics for the potential synergism, even though
many other existing drugs as well as drugs under development may
have related synergistic properties with NAB739. Furthermore, we
show that NAB739 and a widely-used carbapenem antibiotic, mer-
openem, are synergistic against PMR strains that are simultaneously
resistant to carbapenems. Throughout the studies, PMB was used as a
comparator.
2. Materials and methods
2.1. Peptides
NAB739 sulfate was custom-made by Bachem AG (Bubendorf,
Switzerland). The peptide purity, as estimated by HPLC, was 97.3%.
Polymyxin B sulfate was from Sigma-Aldrich (St. Louis, MO, USA;
product number P0972).
2.2. Partner antibiotics
Rifampin, retapamulin and meropenem trihydrate were from
Sigma-Aldrich.
2.3. Bacterial strains
The polymyxin-resistant strains studied are listed in Table 2. The EN
strains are from the ENABLE program, funded by EU and European
Federation of Pharmaceutical Industry Associations (EFPIA). The other
polymyxin-resistant strains are from the University of Cardiff collection
and originate from Thailand (strains #1 through #79) and from Spain
(strain 13115). E. coli ATCC 25922, K. pneumoniae ATCC 13883 and A.
baumannii ATCC 19606 were used as control strains.
2.4. Synergism studies
The synergism was studied by the checkerboard method, where
Fractional Inhibitory Concentrations (FICs) ≤0.5 indicate synergism. It
has been shown that broth microdilution (BMD) and agar dilution (AD)
yield very similar results in polymyxin susceptibility studies [23–27].
We chose AD (according to CLSI [28]) since very recent studies have
shown that colistin is heavily bound to plastic in the microwells,
especially at low concentrations [29], and that AD is superior to broth
dilution methods in colistin susceptibility studies in terms of reprodu-
cibility [30]. Also, a recent study on an outbreak of colistin-resistant K.
pneumoniae relied on the AD method [31].
The checkerboard agar plates (Mueller-Hinton agar [Becton
Dickinson, Oxford, UK]) contained increasing concentrations of
NAB739 or PMB (0.06, 0125, 0.25, 0.5, 1, 2, 4, 8, 16mg/L) and the
partner antibiotic (0.25, 0.5, 1, 2, 4, 8, 16mg/L). No higher con-
centrations were included since they are irrelevant in clinical settings.
The plates also included control plates with no partner antibiotics and
those with no NAB739 or PMB (collectively, polymyxins).
3. Results
Tables 2 and 3 summarize the synergism studies where rifampin and
retapamulin (i.e. the surrogate of lefamulin, see Introduction) were
used as partner antibiotics for NAB739 and its comparator, PMB.
Table 2 shows the MICs of NAB739, PMB, rifampin, and retapamulin
alone as well as the MICs of NAB739 and PMB in the presence of a low
concentration of rifampin or retapamulin (1mg/L and 2mg/L, respec-
tively). The combinations showed significantly reduced MICs for the
polymyxin-resistant strains. The exceptions were E. coli EN303 that was
not susceptible to the combination of polymyxins and rifampin and A.
baumannii EN284 that was not susceptible to the combination of poly-
myxins and retapamulin. However, the lack of synergism was probably
not due to the lack of the OM-permeability increasing action of poly-
myxins, because E. coli EN303 was susceptible to the combination of
polymyxins and retapamulin and A. baumannii EN284 was susceptible
to the combination of polymyxins and rifampin.
The MICs both in the absence and in the presence of the partner
antibiotic were lower for PMB than for NAB739. In most cases, the
difference was 4-fold. On the other hand, the FICs were very similar for
NAB739 and PMB (Table 3). The medians and ranges (in parentheses)
of the FICs against E. coli and K. pneumoniae for each combination were:
NAB739+rifampin, 0.19 (0.13-0.27); PMB+ rifampin, 0.16 (0.08-
0.25); NAB739+retapamulin, 0.19 (0.14-0.28); PMB+ retapamulin,
0.19 (0.09-0.31). The synergism of polymyxins with rifampin against
EN303 was omitted in the range because this strain apparently had high
intrinsic resistance to rifampin. However, EN303 was very susceptible
to the synergistic action of polymyxins and retapamulin. Against A.
baumannii EN284 and EN287, the FICs of NAB+ rifampin were 0.19
Table 1
The structure of polymyxin B (PMB), colistin (polymyxin E) and NAB739. R(FA) defines the fatty acyl tail. The amino acyl residues are numbered as R1 though
R10.a,b
aAmino acyl residues that differ from those in polymyxin B are boxed.
bAbbreviations: cy, cyclic portion indicated with brackets.
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and 0.09, respectively and those of PMB+ rifampin 0.13 and 0.19,
respectively.
No synergism between polymyxins and the partner antibiotics was
seen against the control strains E. coli ATCC 25922 and K. pneumoniae
ATCC 13883 (Table 3). However, against A. baumannii ATCC 19606,
synergism with FIC values ranging from 0.13 to 0.5 was found. We have
previously shown that NAB739 is synergistic with several antibiotics
against polymyxin-susceptible A. baumannii strains [32–34].
We also tested the potential synergy of polymyxins with mer-
openem. No synergism was found against any meropenem-susceptible
strains. Against meropenem-resistant strains (Table 4), the FICs of
NAB739 and PMB against K. pneumoniae EN245 were 0.5 and 0.31,
respectively. Against K. pneumoniae EN233, the corresponding FICs
were 0.38 and 0.5. No synergism was found against K. pneumoniae
strain 13115. Against A. baumannii EN284, the FICs of NAB739 and
PMB were 0.25 and 0.38, respectively. Against A. baumannii EN287, the
Table 2
Synergism of NAB739 and its comparator, polymyxin B (PMB), with the model partner antibiotics rifampin (RIF) and retapamulin (RET) against E. coli, K. pneumoniae
and A. baumannii strains that are resistant to polymyxin B (MIC,> 2mg/L).a
MIC (mg/L) of
NAB739 PMB RIF RET NAB739 PMB NAB739 PMB
Strainb Species Resistance type in the presence of RIF (1mg/L) in the presence of RET (2mg/L)
ATCC 25922 E. coli 1 0.5 16 16 2 0.5 0.5 0.25
EN303 E. coli Col-Rb 16 8 >16 16 8 8 1 0.5
EN481 E. coli mcr-1 >16 8 >16 16 4 0.5 4 1
EN482 E. coli mcr-1 16 8 16 16 4 1 2 1
EN483 E. coli mcr-1 > 16 8 16 8 4 1 2 1
EN484 E. coli mcr-1 > 16 8 8 8 4 0.5 2 1
EN485 E. coli mcr-1 > 16 8 16 16 4 1 4 1
EN486 E. coli mcr-1 > 16 8 8 8 2 0.5 1 0.5
#1 E. coli mcr-1 > 16 16 16 > 16 4 1 4 1
#2 E. coli mcr-1 > 16 8 16 > 16 4 2 2 1
#3 E. coli mcr-1 > 16 8 16 16 4 2 4 1
#4 E. coli mcr-1 > 16 16 16 16 4 1 4 1
ATCC 13883 K. pneumoniae 1 0.25 > 16 > 16 1 0.25 0.5 0.25
EN245 K. pneumoniae Col-R > 16 16 >16 > 16 4 1 4 1
EN233 K. pneumoniae Col-R 16 16 16 > 16 4 1 4 1
#38 K. pneumoniae mcr-1 >16 >16 >16 > 16 4 1 4 1
#72 K. pneumoniae mcr-1 >16 16 >16 > 16 4 1 4 1
#77 K. pneumoniae mcr-1 16 8 >16 > 16 4 1 4 1
#79 K. pneumoniae mcr-1 16 16 >16 > 16 4 1 4 1
13I15 K. pneumoniae Col-R > 16 16 >16 > 16 1 1 4 1
ATCC 19606 A. baumannii 4 0.5 4 > 16 0.125 0.125 0.5 0.25
EN284 A. baumannii Col-R 16 16 4 > 16 1 0.5 16 16
EN287 A. baumannii Col-R 8 4 8 > 16 0.25 0.25 4 2
a ATCC laboratory control strains are included.
b COL-R, colistin-resistant, undefined mechanism of polymyxin resistance.
Table 3
Synergism of NAB739 and its comparator (PMB) with two model partners (rifampin, retapamulin) against polymyxin-resistant strains, as shown by using FIC indices.a
Species Isolate Property FIC of a combination of polymyxins with two model partners (RIF and RET)
NAB739+RIF PMB+RIF NAB739+RET PMB+RET
E. coli ATCC 25922 WT 0.75 0.75 0.56 0.52
EN303 Col-R 0.50 0.50 0.19 0.19
EN481 mcr-1 0.19 0.08 0.19 0.19
EN482 mcr-1 0.19 0.16 0.19 0.19
EN483 mcr-1 0.14 0.16 0.25 0.25
EN484 mcr-1 0.16 0.16 0.25 0.31
EN485 mcr-1 0.19 0.19 0.19 0.19
EN486 mcr-1 0.16 0.16 0.19 0.25
1 mcr-1 0.19 0.19 0.25 0.13
2 mcr-1 0.19 0.25 0.25 0.25
3 mcr-1 0.19 0.25 0.25 0.25
4 mcr-1 0.19 0.19 0.25 0.19
K. pneumoniae ATCC 13883 WT 0.56 0.52 0.56 0.63
EN245 Col-R 0.13 0.08 0.14 0.09
EN233 Col-R 0.27 0.08 0.26 0.09
38 mcr-1 0.13 0.07 0.19 0.09
72 mcr-1 0.13 0.08 0.16 0.09
77 mcr-1 0.26 0.08 0.26 0.19
79 mcr-1 0.26 0.08 0.28 0.13
13115 Col-R 0.13 0.07 0.14 0.09
A. baumannii ATCC 19606 WT 0.13 0.31 0.19 0.50
EN284 Col-R 0.19 0.13 1 0.75
EN287 Col-R 0.09 0.19 0.5 0.56
a FIC values ≤ 0.5 indicate synergism and are shown in cursif.
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corresponding MICs were 0.25 and 0.27. These findings merit more
extensive studies on the potential of the combination of polymyxins
with meropenem and other carbapenems against strains that are si-
multaneously resistant to polymyxins and meropenem.
4. Discussion
It has long been known that polymyxins increase the permeability of
the OM and permeabilize it to other drugs. This property is most easily
recognizable with derivatives such as polymyxin B nonapeptide
(PMBN), NAB7061 and NAB741 that lack any direct antibacterial ac-
tivity [15,16,18–20,32,35], Several other polycationic peptides, such as
linear lipopeptide paenipeptins and unacylated tridecaptin share this
property of polymyxins and drastically sensitize the target bacteria to
rifampin [36,37], clarithromycin [36], and many other antibiotics [37].
Besides the traditional antibiotics, certain novel antibiotics under de-
velopment, such as the lantibiotic NAI-107, are synergistic with poly-
myxins [38].
It is quite noteworthy that the OM-permeabilizing activity of poly-
myxins, and perhaps that of several other polycationic peptides, extend
to enterobacterial strains that display either mutational or acquired
resistance to polymyxins (PMR) strains [12–14]. Here, we showed that
NAB739, too, belongs to the group of agents that permeabilize the OM
of PMR strains to other drugs. Even though PMR strains are still com-
paratively rare [39], they pose a potential threat. NAB739 has ad-
vantages over PMB, such as better efficacy (as shown in murine urinary
tract infection; efficacious dose, one tenth of that of PMB) as well as
better tolerability (as studied in cynomolgus monkeys).
Approx. 6.3 million patients were treated in 2013 in the hospital
wards in Europe, the USA and Japan due to cUTIs caused by E. coli and
K. pneumoniae [40]. These two bacteria cause 80% of all cUTIs treated
in hospitals. In the future, many more of those infections will be caused
by the XDR strains than is already reported [40]. NAB739 may prove to
be a reliable “next generation” polymyxin for clinical use and find much
more role over polymyxins in the therapy of infections caused by XDR
strains. Whether it is more effective and better tolerated than PMB in
the treatment of cUTIs and resulting bacteraemias and septic infections
(as the preclinical studies suggest), remains to be investigated.
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